Your browser doesn't support javascript.
loading
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink, Hiddo J L; Parving, Hans-Henrik; Andress, Dennis L; Bakris, George; Correa-Rotter, Ricardo; Hou, Fan-Fan; Kitzman, Dalane W; Kohan, Donald; Makino, Hirofumi; McMurray, John J V; Melnick, Joel Z; Miller, Michael G; Pergola, Pablo E; Perkovic, Vlado; Tobe, Sheldon; Yi, Tingting; Wigderson, Melissa; de Zeeuw, Dick.
Afiliação
  • Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. Electronic address: h.j.lambers.heerspink@umcg.nl.
  • Parving HH; Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Faculty of Health Science, Aarhus University, Aarhus, Denmark.
  • Andress DL; Pharmaceutical Development, AbbVie, North Chicago, IL, USA.
  • Bakris G; American Society of Hypertension Comprehensive Hypertension Center, University of Chicago Medicine and Biological Sciences, Chicago, IL, USA.
  • Correa-Rotter R; National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico.
  • Hou FF; Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, Guangzhou, China.
  • Kitzman DW; Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Kohan D; Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
  • Makino H; Okayama University, Okayama, Japan.
  • McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Melnick JZ; Pharmaceutical Development, AbbVie, North Chicago, IL, USA.
  • Miller MG; Pharmaceutical Development, AbbVie, North Chicago, IL, USA.
  • Pergola PE; Renal Associates PA, San Antonio, TX, USA.
  • Perkovic V; George Institute for Global Health and University of New South Wales, Sydney, NSW, Australia.
  • Tobe S; Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto and the Northern Ontario School of Medicine, Toronto, ON, Canada.
  • Yi T; Pharmaceutical Development, AbbVie, North Chicago, IL, USA.
  • Wigderson M; Pharmaceutical Development, AbbVie, North Chicago, IL, USA.
  • de Zeeuw D; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Lancet ; 393(10184): 1937-1947, 2019 05 11.
Article em En | MEDLINE | ID: mdl-30995972
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Creatinina / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Insuficiência Renal Crônica / Antagonistas do Receptor de Endotelina A / Atrasentana Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Creatinina / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Insuficiência Renal Crônica / Antagonistas do Receptor de Endotelina A / Atrasentana Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido